Judging from the immunohistochemistry (IHC) expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor2 (HER2), breast cancer can be broadly classified into luminal-like (luminal A/B-like), HER2-positive, and triple-negative [1–4]. This evidence concerns the gene ERBB2 and breast carcinoma.